Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist, and Executive Director of Employer Services at the City of Hope Comprehensive Cancer Center in Duarte, CA.

EGFR Tyrosine Kinase Inhibitors in Advanced BAC
Sun, 11/05/2006 - 16:53
Please Note: New Treatments Have Emerged Since this Original Post
Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

As we established several years ago that it is indeed possible to do clinical trials with more than 50 or even 100 patients with advanced BAC, we were also seeing that those first forays into advanced BAC with standard chemotherapy were somewhat disappoingting (described further in another post). Fortunately, as it became clearer that we needed other options for advanced BAC, we started to see the first cases of patients with BAC who received Iressa on clinical trials who would sometimes have rapid and profound responses to this drug (below showing a difference after just 5 days): BAC pre and post iressa The lung cancer physicians at Memorial Sloan Kettering Cancer Center (MSKCC) reviewed the results from 139 patients who received the EGFR tyrosine kinase inhibitor (TKI) Iressa (gefitinib) as a single agent over a 5 year period and found that a diagnosis of BAC was among the strongest predictors for having a response to Iressa (abstract here).

I wrote and led the SWOG trial that we launched in 2001 to study Iressa at 500 mg daily in advanced BAC, and this is the largest prospective trial in advanced BAC that has ever been conducted (SWOG 0126 abstract here). This trial included two patient groups, one who had not received any chemotherapy and another previously treated with conventional chemotherapy; a total of 138 eligible patients were enrolled from around the US. We saw responses in about 1 in 6 patients, a bit more commonly in patients who hadn’t received any prior treatment. Nearly half of the patients at least didn’t have progression of their disease for several years. While the patient population as whole did about the same as we saw in the prior trial with taxol, several patient groups did better than others on the Iressa trial, including women, patients who developed a rash, never-smokers, and patients who were healthier to begin with Importantly, patients with pure BAC weren’t the only ones to do well with Iressa. Patients with tumors that were adenocarcinoma mixed with BAC did well, and patients with non-mucinous pure BAC did better than those with mucinous BAC. A smaller trial, led by MSKCC, has treated approximately 100 patients with advanced BAC with Tarceva (erlotinib) at 150 mg daily. As in the SWOG trial, one quarter of the patients had been previously treated with chemotherapy. The results of this trial have only been published as an abstract thus far (preliminary results here), but approximately 24% exhibited a response, and those responses have lasted about a year on average. They also found a greater likelihood of response among lifelong non-smokers than former smokers or current smokers, and saw no responses were seen among patients who did not develop a rash on erlotinib. Responses were not restricted to patients with pure BAC and in fact were more commonly seen in tumors that demonstrated adenocarcinoma with BAC than in pure BAC. Taken together, the evidence from these two trials clarify the utility of EGFR TKIs in the treatment of BAC, either in the front-line or salvage setting, although it appears that there remain distinct subsets that will benefit more or less from these agents. It is certainly reasonable to treat BAC with chemotherapy, with or without Avastin, as other types of NSCLC are managed, but EGFR TKIs are generally used early, either as first treatment or as a leading choice shortly thereafter. Right now, I’m leading a trial through SWOG that gives patients with BAC the combination of Tarceva and the anti-angiogenenic agent Avastin (SWOG 0635), since the combination appears to be well tolerated and may be more active than Tarceva alone. Since BAC is generally treated with Tarceva now as an approach of choice, the question is whether we can improve on that with Avastin added, as adding Avastin to carboplatin/taxol has been shown to improve survival in non-squamous advanced NSCLC in general. Other interesting clinical trials of BAC are studying drugs like Alimta (pemetrexed), Velcade (bortezomib), Nexavar (sorafenib), Sutent (Sunitinib), and Erbitux(cetuximab). It is encouraging to see that the interest in BAC is steadily increasing in the lung cancer community, since this may lead to ongoing improvements in treatments for patients with BAC, as well as a better understanding of the disease.

Next Previous link

Previous PostNext Post

Related Content

Spanish Targeted Therapy Lung Cancer Patient Forum 2023
2023 Terapias Dirigidas en el Foro de Pacientes con Cáncer de Pulmón El vídeo completo sin editar está disponible On Demand   View HERE  
Spanish TTF 2023
Únete a nosotros, sábado 12 de agosto a las 9:00 a.m.  En este foro anual de pacientes en vivo, los principales oncólogos torácicos de todo el mundo discuten temas relevantes para los objetivos del cáncer de pulmón, así como mutaciones raras.  
Targeted Therapies in Lung Cancer Patient Forum 2023
Thank you for joining us on Saturday for the 2023 Targeted Therapies in Lung Cancer Patient Forum! The full unedited versions of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage and Second Stage, are now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks.  

Forum Discussions

Hi, I'm sorry you're having these issues.  The type of shoulder pain that feels like nerve pain is most likely nerve pain.  The type of tumor that causes similar shoulder pain...

Thank you so much for the response! I have seen a lot of your post on here and it's really awesome of you to take the time to reply to all...

ONKTALK is tomorrow. 

I hope to see you there.

The forum is now available on demand here.  Don't hesitate to ask questions as they come up. 

Take care,


Hi happybluesun,  Welcome to Grace.   I'm sorry your mom is going through this. 


Driver mutations are mutations that drive (or cause) the cancer.  Having more than one driver mutation is...

Hi Janine, thank you very much for your reply. As of June 2023, my mom has been prescribed Almonertibi Mesilate Tablet, a targeted therapy medicine made by the Chinese company Haosen...

Recent Comments

Thank you so much for the…
By Worried472 on Tue, 09/26/2023 - 12:44
Hi, I'm sorry you're having…
By JanineT GRACE … on Tue, 09/26/2023 - 11:24
The forum is now available…
By JanineT GRACE … on Mon, 09/25/2023 - 14:10
By JanineT GRACE … on Fri, 09/22/2023 - 15:50